<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9B967815-172A-452E-A820-65B16A7525C8"><gtr:id>9B967815-172A-452E-A820-65B16A7525C8</gtr:id><gtr:firstName>Tim</gtr:firstName><gtr:surname>Humphreys</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12003"><gtr:id>091107B4-012E-4536-8976-36C39698D4B6</gtr:id><gtr:title>DNA double strand breaks and genome stability</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12003</gtr:grantReference><gtr:abstractText>Exposure to ionizing radiation causes DNA double-strand breaks (DSBs), which can be repaired, but can also lead to chromosomal rearrangements, a hallmark of cancers. Our research aim is to understand how genome stability is maintained in response to DSBs. To achieve this, we are examining the mechanisms and determinants of DSB repair, including the role of tumour suppressor genes, in preventing break-induced chromosomal rearrangements in normal cells. Further we are examining DSB misrepair and the fate of unrepaired broken chromosomes, to gain new insights into the mechanisms by which such lesions contribute to genome instability and tumourigenesis. These studies, using both fission yeast and mammalian cells, will contribute to our understanding of the mechanisms that maintain genome stability in response to DSBs. Greater knowledge of these mechanisms will provide important insights into how these events drive tumourigenesis, and will enhance our ability to predict and ultimately control the cellular responses to ionizing radiation, which will be of significant clinical value.</gtr:abstractText><gtr:technicalSummary>DNA double strand breaks (DSBs) are highly genotoxic lesions, arising from exposure to ionizing radiation (IR). While normally repaired, such lesions can also promote chromosomal rearrangements and tumourigenesis through oncogene activation and loss of heterozygosity (LOH), resulting in tumour suppressor loss. Despite recent advances, significant gaps remain in our knowledge of DSB repair, and how this relates to genome stability. Our recent studies in fission yeast have identified a number of genes that promote efficient homologous recombination (HR) repair and suppress break-induced chromosomal rearrangements and LOH. A number of these genes are tumour suppressor homologues, including ATR, NBS1, MRE11, BLM, 53BP1 and CHK1 which function directly or indirectly to facilitate efficient HR. Our findings support a general model of break-induced chromosomal rearrangements in which extensive end processing associated with failed or inefficient HR repair promotes chromosomal rearrangements and genome instability. 
We are currently examining the mechanisms and determinants of efficient DSB repair that maintain genome stability. We are also determining the underlying mechanisms of break-induced chromosomal rearrangements and their genetic requirements. Further, we are developing technology to extend our findings from fission yeast to determine whether these tumour suppressors function analogously to suppress break-induced LOH in mammalian cells. 
These studies, using both fission yeast and mammalian cells, will contribute to our understanding of the mechanisms that maintain genome stability in response to DSBs in eukaryotic cells. Greater knowledge of these mechanisms will provide important insights into how these events drive tumourigenesis, and will enhance our ability to predict and ultimately modulate the cellular responses to ionising radiation, which will be of significant clinical value.</gtr:technicalSummary><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3330000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Journal interview</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3477BC42-41F4-4FB3-BB2B-A4D5CB8E1908</gtr:id><gtr:impact>Interviewed for 'Wired' magazine for an article entitled 'From research scientist to project manager: outsourcing the lab' published 10th October 2012.

This was widely read by Wired readers</gtr:impact><gtr:outcomeId>kWj71xrFYyW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://markpiesing.com/2012/10/19/from-research-scientist-to-project-manager-outsourcing-the-lab/</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk (Belfast)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>45A80BB9-44F2-4E23-8DAC-07A360723474</gtr:id><gtr:impact>'Chromosome breaks, chromatin and cancer' Invited presentation to the Centre for Cancer Research and Cell Biology, Queen's University, Belfast 28th May 2015.</gtr:impact><gtr:outcomeId>56e00a29bb7a84.26342915</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Targeting histone H3K36me3-deficient cancers'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>211ECC92-4596-4489-B6E4-6DB2E501A77D</gtr:id><gtr:impact>Invited speaker at 'Response to DNA damage: from molecule to disease.' Conference with over 500 delegates, Egmond aan Zee, The Netherlands, April 17-22, 2016.</gtr:impact><gtr:outcomeId>58c6cdfdc2dd01.03562313</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk (North Carolina)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D710E2D9-9D38-4B9D-A692-01574EB907DB</gtr:id><gtr:impact>Chromosome breaks, chromatin and cancer' Invited presentation to the UNC Lineberger School of Medicine, Biochemistry and Biophysics, Chapel Hill, North Carolina, USA, 5th May 2015.</gtr:impact><gtr:outcomeId>56e009d7c8f7a9.25900799</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk (Bangor)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>477FA1F9-B293-4D53-9727-08B87DB58100</gtr:id><gtr:impact>'Targeting histone H3K36me3-deficient cancers'. Invited speaker at the North West Cancer Research Bangor 10th Anniversary Symposium, 20th November 2014.</gtr:impact><gtr:outcomeId>56e008e6501622.45047092</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI conference (Liverpool)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0216FF60-BA60-48BA-931F-3033938EFC1A</gtr:id><gtr:impact>'Exploiting synthetic lethality to target histone H3K36me3-deficient cancers'. Invited speaker at National Cancer Research Institute Conference, Liverpool, 2nd November 2015</gtr:impact><gtr:outcomeId>56e00731ecfc85.25511483</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Epigenetics conference (Cambridge)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B49EEC4C-13D2-40E8-ABD3-B06884C53C36</gtr:id><gtr:impact>'Targeting histone H3K36me3-deficient cancers'. Invited speaker at Epigenetics in Drug Discovery Conference, Buckingham House, Murray Edwards College, Cambridge, 26-27th January 2016</gtr:impact><gtr:outcomeId>56e007a81331a1.73650751</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk (Dresden)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1EDBB1E9-4D9B-4E0E-87AD-6224CD7DDD9F</gtr:id><gtr:impact>'Exploiting replication stress to target histone H3K36me3-deficient cancers' Invited seminar at the Technische Universitaet Dresden BioinnovationsZentrum, 11th November 2015</gtr:impact><gtr:outcomeId>56e00aece6f711.54547440</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Fission Yeast meeting (Japan)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6836C2D6-8C40-4AB8-A619-3A6287FB59C2</gtr:id><gtr:impact>Talk by post-doc from my lab</gtr:impact><gtr:outcomeId>56e005cc8acef1.76956899</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B1A88CA9-AE8C-4B89-AA26-1F4F408A8330</gtr:id><gtr:impact>Interview with Fred Dinenage on ITV Meridian, broadcast after main news on ITV South. 6pm 2nd November 2015.</gtr:impact><gtr:outcomeId>56e00b7c7cc224.47379791</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chromatin conference (Berlin)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DC210483-1366-4584-835B-575FE40060E6</gtr:id><gtr:impact>Collaborations</gtr:impact><gtr:outcomeId>56e00433c483f3.72110840</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cancer conference (Australia)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>62106CDA-3412-4127-9CED-3B7CB7EA4C44</gtr:id><gtr:impact>'Targeting histone H3K36me3-deficient cancers' Invited International Speaker at the 28th Lorne Cancer Conference, Mantra Lorne, Lorne, Victoria, Australia, 11-13 February 2016</gtr:impact><gtr:outcomeId>56e0080ea44054.03348935</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk (North Carolina)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A10711E3-AC5D-4133-AAAB-1C0386097D6B</gtr:id><gtr:impact>'Chromosome breaks, chromatin and cancer' Invited presentation at the National Institute for Environmental Health Studies, Chapel Hill, North Carolina, USA, 4th May 2015.</gtr:impact><gtr:outcomeId>56e0097d1ac294.71273483</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Yeast Group Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>012A4C94-13E5-4D98-868F-8857C62C9F96</gtr:id><gtr:impact>Oral presentation by post-doc from my lab</gtr:impact><gtr:outcomeId>56e0053b90c379.83889783</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to group from six schools</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E962BFA9-DFBB-4F0C-AB49-BCC1BA3B9A0B</gtr:id><gtr:impact>Presented talk entitled 'Genome Instability and Cancer' to 85 Year 12 students from six schools as part of the CRUK Oxford Cancer Centre Open Day 11th March 2015</gtr:impact><gtr:outcomeId>56e00c73d4cf14.89295815</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2BA35F3C-C4E8-4519-924F-51AB12D20C47</gtr:id><gtr:impact>Live interview with Nick Piercey, Radio Oxford, discussing our finding that we can target cancer cells with a particular mutation, broadcast at 1.12pm 2nd November 2015.</gtr:impact><gtr:outcomeId>56e00bdb4bb363.91183219</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk (Oxford)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>866289C7-43EE-4F7C-89CE-36A8F4812471</gtr:id><gtr:impact>'Exploiting replication stress to target histone H3K36me3-deficient cancers' Invited seminar at the Weatherall Institute for Molecular Medicine, University of Oxford, 20th October 2015</gtr:impact><gtr:outcomeId>56e00a87667087.72463019</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Exploiting paradigms from S. pombe to target histone H3K36me3-deficient cancers'.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4E73B7A8-48CD-4593-A56D-CC5089855C22</gtr:id><gtr:impact>Invited presentation, as part of the 'Genes to Cells' seminar series, The Crick Institute, London; 23rd June, 2016.</gtr:impact><gtr:outcomeId>58c6ccdc3dc8e4.40815621</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>33032</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centenary Award: Project title: A quantitative assay for DNA double-strand break-induced genome instability in human cells.</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>  H3RWGJX/TH/RWGJO</gtr:fundingRef><gtr:id>EECC724E-D8B5-4C53-9B4D-72406756DD7A</gtr:id><gtr:outcomeId>58c6cb2f128082.95779979</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>OCRC Development Fund Award</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>DA8C7108-BC56-452E-BC03-A7C609EB12CB</gtr:id><gtr:outcomeId>UWLwmzCMwr3</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Oxford Cancer Research Centre (OCRC)</gtr:department><gtr:description>OCRC Development fund award</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:fundingRef>CRUKDF 0715-TH</gtr:fundingRef><gtr:id>E4CD2BDF-BE4F-4561-BAAB-50286ED2A8EA</gtr:id><gtr:outcomeId>56dff731557bf8.01233897</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The use of checkpoint kinase inhibitors in targeting histone H3K36me3-deficient cancers</gtr:description><gtr:grantRef>MC_PC_12003</gtr:grantRef><gtr:id>A6359D80-62D7-4957-AE80-C80DAF82E8C8</gtr:id><gtr:impact>This patent application was filed with the aim of attracting interest from pharmaceutical companies in the targeted use of checkpoint kinase inhibitors to treat histone H3K36me3-deficient cancers. This has now been achieved and hence the patent application has been allowed to lapse</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56e01186869cf2.16728631</gtr:outcomeId><gtr:patentId>1309238.2</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>TREATMENT</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Special Research Programme review panel (Austria)</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>2C795B0F-03C4-4BE8-8380-74408BBB16E9</gtr:id><gtr:impact>Austrian Science Fund (FWF) Special Research Programme review panel, Vienna, 13-15 Oct 2015.</gtr:impact><gtr:outcomeId>56e02205b1dbf8.34506133</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific evaluation committee</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>F721FAF0-8E26-4397-B784-300F8FCD2E42</gtr:id><gtr:outcomeId>5460fcad406502.16846875</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>French National Cancer Institute (INCa) Biology and Basic Sciences for Cancer Research -Scientific Evaluation committee</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>9B3F4690-75B5-49B2-9D0F-F6A2528663A0</gtr:id><gtr:outcomeId>58c6cf35af8772.44204908</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific evaluation committee (France)</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>EB586F75-F1C4-4A46-9A28-353887CF207D</gtr:id><gtr:impact>French National Cancer Institute (INCa) Biology and Basic Sciences for Cancer Research-2015 Scientific Evaluation committee 21-23 Jan 2015</gtr:impact><gtr:outcomeId>56e02265e41367.83990287</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Austrian Science Fund (FWF) Special Research Programme review panel</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>EC2C7E01-764E-4185-A2E9-12178C7037DF</gtr:id><gtr:impact>This is the major flagship funding for the Austrian Science Fund. As part of the panel we made financial decisions relating to the allocation of funding.</gtr:impact><gtr:outcomeId>bzC6XHPsSpz</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Our studies indicate that patients with histone H3K36me3-deficient cancers would benefit from treatment with the WEE1 inhibitor, AZD1775 (Pfizer et al., Cancer Cell, 2015)</gtr:description><gtr:id>EFC8A8BD-4880-4DB4-9F26-5E065228F025</gtr:id><gtr:impact>We anticipate that the use of WEE1 inhibitors as a treatment for histone H3K36me3-deficient cancers will be taken into clinical trials.</gtr:impact><gtr:outcomeId>56e01e7036ed92.75459770</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Proposed treatment for histone H3K36me3-deficient cancers</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We have identified (in collaboration with the laboratory of Anderson Ryan) a biomarker for the detection of histone H3K36me3-deficient cancers.
This biomarker can be used to determine the suitability of patients for treatment with the WEE1, ATR or CHK1 checkpoint kinase inhibitors</gtr:description><gtr:id>68730DB5-C82E-48F3-A626-645B13275BC8</gtr:id><gtr:impact>A number of research groups and consortia are now testing levels of histone H3K36me3 deficiency in different cancer types with the view to determining suitability for treatment with checkpoint kinase inhibitors.</gtr:impact><gtr:outcomeId>56e01d7ba123d2.75605088</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Biomarker for the detection of H3K36me3-deficient cancers</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C09F9A82-23B1-40A7-AC77-B0CBFAF1D1DA</gtr:id><gtr:title>Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76532b54344c18c0287d1f9e3a50d7c9"><gtr:id>76532b54344c18c0287d1f9e3a50d7c9</gtr:id><gtr:otherNames>Pfister SX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>56dff4f22d7095.97204869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE6AE6B2-2B5C-4A1E-8B89-0E4B82B8147A</gtr:id><gtr:title>Set2 Methyltransferase Facilitates DNA Replication and Promotes Genotoxic Stress Responses through MBF-Dependent Transcription.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eefd473485aa0299807c5071d849ae0"><gtr:id>3eefd473485aa0299807c5071d849ae0</gtr:id><gtr:otherNames>Pai CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aaa8120d3b776.23871173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFCEAA0A-B06A-4BD0-8248-83FB149BE271</gtr:id><gtr:title>SET-ting the stage for DNA repair.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f62325b0b63620df1d4108189196b52"><gtr:id>0f62325b0b63620df1d4108189196b52</gtr:id><gtr:otherNames>Jha DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>5460f1bf99c783.69635177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9F71A7C-E63D-40F9-9B81-91F10E22E42E</gtr:id><gtr:title>MRG15-mediated tethering of PALB2 to unperturbed chromatin protects active genes from genotoxic stress.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/264df43e701a1b22e92a318c275ab053"><gtr:id>264df43e701a1b22e92a318c275ab053</gtr:id><gtr:otherNames>Bleuyard JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5aaa8121464303.49548873</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E176A07D-5D54-4153-A780-51339CDD711B</gtr:id><gtr:title>SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76532b54344c18c0287d1f9e3a50d7c9"><gtr:id>76532b54344c18c0287d1f9e3a50d7c9</gtr:id><gtr:otherNames>Pfister SX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460f1bf73b256.23331330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3765C32A-97A2-4374-8275-23D975B047B0</gtr:id><gtr:title>A role for human homologous recombination factors in suppressing microhomology-mediated end joining.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3444cb2318a42e95d1af1aed72dd53a7"><gtr:id>3444cb2318a42e95d1af1aed72dd53a7</gtr:id><gtr:otherNames>Ahrabi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5a6dcaed1d0668.68682872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94EDEBAC-5FD2-47E8-9CE0-CA0DED16463A</gtr:id><gtr:title>Use of the HPRT gene to study nuclease-induced DNA double-strand break repair.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cbed6d00ba01367cf03b1ff7748fe54"><gtr:id>4cbed6d00ba01367cf03b1ff7748fe54</gtr:id><gtr:otherNames>Gravells P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56dff4f20137f8.29098091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CE347A6-9908-4534-93A9-BDAC192B7BA8</gtr:id><gtr:title>The spliceosome-associated protein Nrl1 suppresses homologous recombination-dependent R-loop formation in fission yeast.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77075c5c130341683cd152c2d99f5bc9"><gtr:id>77075c5c130341683cd152c2d99f5bc9</gtr:id><gtr:otherNames>Aronica L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>56dff4f27ed7e7.62542786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50F219C7-F0F4-4C70-B97F-B0D9DD4EB49A</gtr:id><gtr:title>The DNA damage checkpoint pathway promotes extensive resection and nucleotide synthesis to facilitate homologous recombination repair and genome stability in fission yeast.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b03243f9398a243f7b3c64c855d49d2"><gtr:id>3b03243f9398a243f7b3c64c855d49d2</gtr:id><gtr:otherNames>Blaikley EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5460f18c5b8977.31448268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>453A68C6-8012-4EF7-8CA7-554F4129D6DC</gtr:id><gtr:title>Identifying new targets for cancer drug 5'-fluorouracil.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31ad6b85a49a748ce0a34a68316c0781"><gtr:id>31ad6b85a49a748ce0a34a68316c0781</gtr:id><gtr:otherNames>Humphrey TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>56dff4f25d92b8.41269384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DE4D78C-9B0E-496F-B78C-77CB1C91F48D</gtr:id><gtr:title>A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eefd473485aa0299807c5071d849ae0"><gtr:id>3eefd473485aa0299807c5071d849ae0</gtr:id><gtr:otherNames>Pai CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5460f1bf4b48c1.16818498</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12003</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>